Phase II Non-Randomized Two Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arm 1) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Apr 2016 Status changed from not yet recruiting to recruiting.
- 28 Mar 2016 Planned End Date changed from 1 Jul 2028 to 1 Oct 2028 as reported by ClinicalTrials.gov.